With 20% QoQ growth in the US and high other operating income of Rs 2bn (against Rs 1.4bn in the second quarter and Rs 327mn in 3QFY15), Lupin reported 26.1% EBITDA margin, up 500bps sequentially. US sales shot up US$ 34mn QoQ, largely driven by Fortamet, aided by ramp-up in brands and seasonal Ceph sales.